20.23 USD
▼-0.07-0.34%
盘后 25.06 0.00%
2026-11-19
市值
$1.36B
市盈率
—
EPS
-3.56
股息率
—
52 周区间
8.73 – 51.72
成交量
1.20M
Beta
1.13
目标价
58.14
52W 低 8.7352W 高 51.72
价格走势
公司简介
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase ...